Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences' Third Quarter 2025 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences Inc (CSTL)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Portolan Capital Management George Mccabe | 1,729,463 | $67,276,111 | +15% | 3.6% |
| 2. | AIGH Investment Partners Orin Hirschman | 624,719 | $24,301,569 | -12% | 5.88% |
| 3. | Renaissance Technologies Jim Simons | 493,100 | $19,181,590 | -13% | 0.03% |
| 4. | Citadel Investment Group Ken Griffin | 366,356 | $14,251,249 | +47% | 0% |
| 5. | Millennium Management Israel Englander | 308,914 | $12,016,755 | -47% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.27 | 2,500 | $43,175.00 | 9,065 | 2023-06-05 | Filing | |
| $11.23 | 2,300 | $25,829.00 | 6,565 | 2023-06-05 | Filing | |
| $21.50 | 1,162 | $24,983.00 | 2,968 | 2022-11-29 | Filing | |
| $18.77 | 220 | $4,129.40 | 1,806 | 2022-05-12 | Filing | |
| $18.76 | 1,100 | $20,636.00 | 1,586 | 2022-05-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $38.61 | 171 | $6,602.31 | 83,698 | 2026-02-04 | Filing | |
| $37.82 | 646 | $24,433.01 | 83,869 | 2026-02-04 | Filing | |
| $39.91 | 3,200 | $127,721.60 | 84,515 | 2026-02-03 | Filing | |
| $40.01 | 4,017 | $160,732.22 | 87,715 | 2026-01-20 | Filing | |
| $40.10 | 1,339 | $53,688.54 | 29,513 | 2026-01-06 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,105,246 | $120,794,069 | 0% | |
| 2. | 2,199,829 | $85,573,349 | 0% | |
| 3. | 2,115,237 | $82,282,719 | 0.82% | |
| 4. | 1,807,644 | $70,317,352 | 0.04% | |
| 5. | 1,143,799 | $44,494,673 | 0.01% |
News See All
Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2025 Earnings Call Transcript
Operator: Good afternoon all, and thank you for joining us for the Castle Biosciences' Q2 2025 Earnings Call. As a reminder, this call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2025 Earnings Call Transcript
Operator: Good afternoon and welcome to Castle Biosciences First Quarter 2025 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2024 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences Third Quarter 2024 Conference Call. As a reminder, today's call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences Second Quarter 2024 Conference Call. As a remainder, today's call is being recorded.
Castle Biosciences, Inc. (NASDAQ:CSTL) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences First Quarter 2024 Conference Call. As a remainder, today's call is being recorded.
What Makes Castle Bioscience (CSTL) a Prospective Investment?
RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds released “The RiverPark/Next Century Growth Fund” Q4 2023 investor letter in partnership with Next...
Does Castle Bioscience (CSTL) Have Robust Growth Prospects?
Next Century Growth Investors, LLC, an investment Management Company, released its “SMID Cap Growth Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here.
Hedge Fund Resource Center